A two-centre phase 2 trial randomised 253 men due for radiotherapy to standard care or to radiotherapy covering every site detected on PSMA-PET. At a median 66 months, five-year failure-free survival was 66% with PSMA-guided treatment against 62%, a difference the trial did not count as a benefit. Freedom from a rising PSA was 72% against 65%, with the largest difference in high-risk men and those treated after prostatectomy.
Why it is interesting: Randomised evidence on whether finding and treating more lesions changes outcomes, ahead of the phase 3 PATRON trial.
Abstract — the authors' own words, CC BY
Background
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves lesion detection, leading to treatment intensification via PSMA-guided radiotherapy (PSMAgRT), but its impact on patient outcomes remains undefined. Objective
We evaluated whether PSMAgRT improves failure-free survival (FFS). Design, setting, and participants
This phase 2, two-center, open-label randomized trial enrolled patients planned for standard-of-care (SOC) radiotherapy (RT). Intervention
Patients were randomized 1:1 to SOC or PSMAgRT to all detected sites across four strata: salvage post-radical prostatectomy (RP), high-risk, oligometastatic, and salvage post-RT. Between 2018 and 2021, 262 patients were randomized (253 treated/analyzed). Outcome measurements and statistical analysis
The primary FFS end point (measured from RT completion) comprised prostate-specific antigen (PSA)/radiological progression, next-line therapy, or death. Secondary end points included freedom from biochemical progression (FFBP; PSA rise ≥0.2 ng/ml post-RP or ≥2 ng/ml above nadir in other strata). Prespecified analyses used a one-sided threshold of p 1 Results and limitations
Among 253 patients, median follow-up was 66 mo (range 9-91). The 5-yr primary FFS was 66% with PSMAgRT versus 62% in controls (hazard ratio [HR] = 0.80; one-sided 90% CI, upper bound 1.04; p 1 = 0.14). FFBP favored PSMAgRT: 72% versus 65% overall (subdistribution HR [sHR] 0.70, one-sided 90% CI upper bound 0.92; p 1 = 0.048), 81% versus 66% in patients with high-risk disease (sHR 0.54; p 1 = 0.07), and 80% versus 68% in patients in post-RP stratum (sHR 0.54; p 1 = 0.037). In an exploratory, post hoc analysis combining patients with high-risk disease and those in the post-RP stratum, FFBP favored PSMAgRT (sHR 0.54, 95% CI = 0.32-0.91; two-sided p = 0.02). Only one grade ≥3 event was possibly related to dose escalation. Limitations include a phase 2 design with a heterogeneous population. Conclusions
Although the primary FFS end point was not met in the overall population, treatment-effect estimates favored PSMAgRT in the high-risk and post-RP strata. These findings provide a meaningful rationale for the target populations currently being evaluated in the definitive phase 3 PATRON trial. Trial registration
ClinicalTrials.gov NCT03525288.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.